Tauroursodeoxycholic Acid (TUDCA)

Catalog No.S3654

For research use only.

Tauroursodeoxycholic acid (TUDCA) is the taurine conjugate of ursodeoxycholic acid (UDCA) and acts as a mitochondrial stabilizer and anti-apoptotic agent in several models of neurodegenerative diseases, including AD, Parkinson's diseases (PD), and Huntington's diseases (HD).

Tauroursodeoxycholic Acid (TUDCA) Chemical Structure

CAS No. 14605-22-2

Selleck's Tauroursodeoxycholic Acid (TUDCA) has been cited by 22 publications

Purity & Quality Control

Choose Selective Apoptosis related Inhibitors

Biological Activity

Description Tauroursodeoxycholic acid (TUDCA) is the taurine conjugate of ursodeoxycholic acid (UDCA) and acts as a mitochondrial stabilizer and anti-apoptotic agent in several models of neurodegenerative diseases, including AD, Parkinson's diseases (PD), and Huntington's diseases (HD).
In vitro

Tauroursodeoxycholic acid (TUDCA) is an endogenous hydrophilic tertiary bile acid produces in humans at a low level. In ER stress conditions, TUDCA treatment of MSCs (mesenchymal stem cells) reduces the activation of ER stress-associated proteins, including GRP78, PERK, eIF2α, ATF4, IRE1α, JNK, p38, and CHOP, and inhibits the dissociation between GRP78 and PERK, resulting in reduced ER stress-mediated cell death. TUDCA treatment increases PrPC (Cellular prion protein) expression. TUDCA regulates stem cell differentiation into various lineages such as adipogenic and osteogenic lineages. TUDCA attenuates ER stress, prevents unfolded protein response dysfunction, and stabilizes mitochondria. Under ER stress, treatment with TUDCA significantly increases the expression of BCL-2 and significantly decreases the expression of Bax, cleaved caspase-3, and cleaved PARP-1, compared with that of untreated cells[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO cells MUnGeY5kfGmxbjDhd5NigQ>? NWTSNZlZSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVT1J3IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[nlibIXjbYZmemG|ZTDhd5NigSxiRVO1NF0{OCEQvF2= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNyN{K5OEc,OTh|MEeyPVQ9N2F-
Sf9 M4PsdGZ2dmO2aX;uJIF{e2G7 MkTZWHBgXFKDTmPQU3JVTVJ8IIXweIFs\SCrbjDt[Y1jemGwZTD2[ZNq[2ynczDmdo9uKEK|ZYCt[ZhxemW|c3nu[{BU\jliY3XscJMtKEuvPUSuNe69VQ>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODZ2OES3NEc,OTB4NEi0O|A9N2F-
MDCK M{LFOWZ2dmO2aX;uJIF{e2G7 MnK3WHBgXFKDTmPQU3JVTVJ8IIXweIFs\SCrbjDPZZRxOy2neIDy[ZN{cW6pIF3ER2sh[2WubIOsJGtuRTZwNt88US=> M4nFUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzMEmzPVQyLz5zMUC5N|k1OTxxYU6=
HEK293 MVTGeY5kfGmxbjDhd5NigQ>? M2LNXlkxKG2rboO= MkTaTY5pcWKrdHnvckBw\iCqdX3hckBCXFhiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4hwdGmwZTDy[Yxm[XOnIH\yc40hVFCFIH3lZZN2emWmIHX2[ZJ6KDNyIIPlZ5Mh\m:{IEmwJI1qdnNiYomgTHZCKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2xNE4{|ryP MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF4NUK0NUc,OjhzNkWyOFE9N2F-
Sf9 Ml[0SpVv[3Srb36gZZN{[Xl? MkLoWHBgXFKDTmPQU3JVTVJ8IIXweIFs\SCrbjDt[Y1jemGwZTD2[ZNq[2ynczDpd49t[XSnZDDmdo9uKEK|ZYCt[ZhxemW|c3nu[{BU\jliY3XscJMtKEuvPUGxMlnPxE1? MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2MESyOFAoRjF{NEC0NlQxRC:jPh?=
CHO Mn\ySpVv[3Srb36gZZN{[Xl? NE\MPFZVWF:WUlHOV3BQWlSHUkqgeZB1[WunIHnuJG51[3BvZYjwdoV{e2mwZzDDTG8h[2WubIOsJGtuRTF2zszN MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86PDh4MUmxK|46PDh4MUmxQE9iRg>?
COS MYjGeY5kfGmxbjDhd5NigQ>? M2LwbnRRZ1SUQV7TVG9TXEWUOjDpcohq[mm2aX;uJI9nKFSjdYLvZ4hwdGG2ZTD1dJRic2ViaX6gRXNDXC2neIDy[ZN{cW6pIFPPV{Bk\WyuczygT4k:OjkQvF2= NUi1ZY9yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUS1PFc5PSd-OUS1PFc5PTxxYU6=
HuH7 M4TuU2N6fG:ycn;0[YN1cX[nIHHzd4F6 M3v2eFYhcHK| NYjUWGdCS3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDD0eY5q[2GveXPpck1qdmS3Y3XkJGVTKHO2cnXzd{BqdiCqdX3hckBJfUh5IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhS0iRUDDtVm5CKGyndnXsd{Bi\nSncjC2JIhzew>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd{OUG4Okc,Ojd5MkmxPFY9N2F-
HuH7 MoDIR5l1d3C{b4TlZ5RqfmViYYPzZZk> NV7UU3VGPiCqcoO= MoX0R5l1d3C{b4TlZ5RqfmViYXP0bZZqfHliYXfhbY5{fCCGQ1GtbY5lfWOnZDDFVkB{fHKnc4OgbY4hcHWvYX6gTJVJPyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDYRnB2KG2UTlGgcIV3\Wy|IHHmeIVzKDZiaILz M{HEeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{K5NVg3Lz5{N{eyPVE5PjxxYU6=
HuH7 NETBVYVEgXSxcILveIVkfGm4ZTDhd5NigQ>? NFyxPVU3KGi{cx?= MYnDfZRweHKxdHXjeIl3\SCjY4Tpeol1gSCjZ3HpcpN1KHS3bnnjZY16[2mwLXnu[JVk\WRiRWKgd5Rz\XO|IHnuJIh2dWGwIFj1TFch[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iWFLQeUBuWk6DIHzleoVteyCjZoTldkA3KGi{cx?= NWDTfIljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NlkyQDZpPkK3O|I6OTh4PD;hQi=>
HuH7 MX\DfZRweHKxdHXjeIl3\SCjc4PhfS=> MnzWOkBpenN? MWfDfZRweHKxdHXjeIl3\SCjY4Tpeol1gSCjZ3HpcpN1KESFQT3pcoR2[2WmIFXSJJN1emW|czDpckBpfW2jbjDIeWg4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gXGJReyCvUl7BJIxmfmWuczDh[pRmeiB4IHjydy=> NUHsVXRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NlkyQDZpPkK3O|I6OTh4PD;hQi=>
HuH7 NVTpVHluS3m2b4Dyc5Rm[3SrdnWgZZN{[Xl? MXK2JIhzew>? MmrhR5l1d3C{b4TlZ5RqfmViYXP0bZZqfHliYXfhbY5{fCC2dX7pZ4FugWOrbj3pcoR2[2WmIFXSJJN1emW|czDpckBpfW2jbjDIeWg4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gXGJReyCvUl7BJIxmfmWuczDh[pRmeiB4IHjydy=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd{OUG4Okc,Ojd5MkmxPFY9N2F-
HuH7 MXfDfZRweHKxdHXjeIl3\SCjc4PhfS=> MlfrOkBpenN? NWDuSZRYS3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDD0eY5q[2GveXPpck1qdmS3Y3XkJGVTKHO2cnXzd{BqdiCqdX3hckBJfUh5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBZSlC|L2jCVJUhemG2aX:gZYZ1\XJiNjDodpM> NUXSZ2FbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NlkyQDZpPkK3O|I6OTh4PD;hQi=>
HuH7 NYXseXNPS3m2b4Dyc5Rm[3SrdnWgZZN{[Xl? M3XkT|EhdU1? M1W5[lI1KGi{cx?= NVLSNWQ3S3m2b4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDER2EucW6mdXPl[EBk\WyuIHTlZZRpKGmwIHj1cYFvKEi3SEegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZZQhOSCvTTDwdoVqdmO3YnH0[YQhf2m2aDDj[YxteyCob3zsc5dm\CCkeTDER2Eh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNlQhcHK|IHL5JG1VXC:LTlPFUGwh[XO|YYm= NXPyTmo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NlkyQDZpPkK3O|I6OTh4PD;hQi=>
HuH7 NUWxfFRtS3m2b4Dyc5Rm[3SrdnWgZZN{[Xl? M1zLcFYhcHK| M{PBO2N6fG:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RidIXubYNidXmlaX6tbY5lfWOnZDDFVkB{fHKnc4OgbY4hcHWvYX6gTJVJPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGJKWC:JUmC3PEBuWk6DIHzleoVteyCjZoTldkA3KGi{cx?= MlnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MkmxPFYoRjJ5N{K5NVg3RC:jPh?=
HEK293 M1nmRmZ2dmO2aX;uJIF{e2G7 MmTqUo9vNWOxbYDleIl1cX[nIHnubIljcXSrb36gc4YhcHWvYX6gRXRZKGW6cILld5Nm\CCrbjDISWszQTNiRnzwMWlvKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFzQR{BpgWS{b3z5d4l{KGK7IFzpcoV4\WG4ZYKtRpVzcyCybH;0JIFv[Wy7c3nz NWr3SmtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOlUzPDFpPkK4NVY2OjRzPD;hQi=>
Assay
Methods Test Index PMID
Western blot p-Akt / Akt ; PrPc ; CHOP / Caspase-12 / Cleaved caspase-12 ; RIPK1 / RIPK3 / p-RIPK1 / p-RIPK3 28004805 29721028
Growth inhibition assay Cell viability 30038553
In vivo TUDCA is effective for treating cholestatic liver diseases. It also has an ameliorating effect on several diseases, including neurodegenerative diseases, osteoarthritis, vascular diseases, and diabetes. In a murine hindlimb ischemia model, TUDCA-treated mesenchymal stem cells (MSCs) transplantation augments the blood perfusion ratio, vessel formation, and transplanted cell survival more than untreated MSC transplantation does. Augmented functional recovery following MSC transplantation is blocked by PrPC downregulation[1]. Several studies in animals have shown that TUDCA, an endogenous ambiphilic bile acid, can inhibit unfolded protein response dysfunction and ameliorate ER stress. TUDCA administration attenuates HDM-induced ER stress, airway inflammation, mucus metaplasia, airway remodeling, and methacholine-induced AHR[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Mesenchymal stem cells (MSCs)
  • Concentrations: 100 μM
  • Incubation Time: 30 min
  • Method:

    MSCs are washed twice with phosphate buffer saline (PBS), and fresh α-MEM supplemented with 10% FBS is added. To investigate the apoptosis signaling pathway, MSCs are pretreated with TUDCA (100 μM) at 37 °C for 30 min and then treated with H2O2 (200 μM) for various times (0, 2, 4, 6, or 8 h). To assess another cell signaling pathway, MSCs are treated with an Akt inhibitor (10−6 M) for 30 min at 37 °C before treatment with TUDCA.

Animal Research:

[2]

  • Animal Models: House dust mite-induced allergic airway disease mouse model (background: C57BL/6 NJ mice)
  • Dosages: 0.5, 1, and 5 mg/kg body wt
  • Administration: via the nasopharynx

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 499.70
Formula

C26H45NO6S

CAS No. 14605-22-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04114292 Recruiting Drug: Tauroursoursodeoxycholic acid brand name Tudcabil Ulcerative Colitis Washington University School of Medicine|Crohn''s and Colitis Foundation January 17 2019 Phase 1
NCT01899703 Completed Drug: GSK2330672|Drug: Placebo|Drug: Ursodeoxycholic acid Cholestasis Intrahepatic GlaxoSmithKline March 10 2014 Phase 2
NCT01171859 Completed Drug: Doxycycline + Tauroursodeoxycholic acid Transthyretin Amyloidosis IRCCS Policlinico S. Matteo July 2010 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tauroursodeoxycholic Acid (TUDCA) | Tauroursodeoxycholic Acid (TUDCA) supplier | purchase Tauroursodeoxycholic Acid (TUDCA) | Tauroursodeoxycholic Acid (TUDCA) cost | Tauroursodeoxycholic Acid (TUDCA) manufacturer | order Tauroursodeoxycholic Acid (TUDCA) | Tauroursodeoxycholic Acid (TUDCA) distributor